Bionomics Ltd
February 27, 2024
CNS/Neurological
Bionomics, a publicly listed clinical late-stage company focused on addressing unmet needs in CNS. We are developing BNC-210, a Ph3-Ready First- and-Best-in-Class α-7 Nicotinic Receptor for the Treatment of Neuropsychiatric Disorders. BNC-210 has received Fast Trak designation for Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder (SAD).
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}